ScandiDos AB (OSTO:SDOS) 10-Year RORE % : -17.40% (As of Apr. 2026)


OSTO:SDOS ScandiDos AB OSTO:SDOS
47 GF Score
Price kr0.85
GF Value kr1.14
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is ScandiDos AB 10-Year RORE %?

ScandiDos AB OSTO:SDOS +6.25% 47 10-Year RORE % is -17.40 as of Apr. 2026. GuruFocus rates OSTO:SDOS with a GF Score™ of 47/100 and a GF Value™ of kr1.14 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 428 Medical Devices & Instruments companies, ScandiDos AB ranks worse than 78.27% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. ScandiDos AB's 10-Year RORE % for the quarter that ended in Apr. 2026 was -17.40%.

The industry rank for ScandiDos AB's 10-Year RORE % or its related term are showing as below:

OSTO:SDOS's 10-Year RORE % is ranked worse than
78.27% of 428 companies
in the Medical Devices & Instruments industry
Industry Median: 0.735 vs OSTO:SDOS: -17.40

ScandiDos AB  (OSTO:SDOS) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


ScandiDos AB 10-Year RORE % Related Terms


ScandiDos AB 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for ScandiDos AB's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ScandiDos AB 10-Year RORE % Chart

ScandiDos AB Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.22 -7.22 -16.48 -20.58 -17.40

ScandiDos AB Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.58 0.00 0.00 -20.79 -17.40

OSTO:SDOS vs ABT, SYK, MDT: 10-Year RORE % Comparison

For the Medical Devices subindustry, ScandiDos AB's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ScandiDos AB 10-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ScandiDos AB's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where ScandiDos AB's 10-Year RORE % falls into.


OSTO:SDOS
47GF Score
ScandiDos AB OSTO:SDOS
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ScandiDos AB 10-Year RORE % Calculation

ScandiDos AB's 10-Year RORE % for the quarter that ended in Apr. 2026 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.06--0.584 )/( -3.012-0 )
=0.524/-3.012
=-17.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of -17.40 mean?
ScandiDos AB (OSTO:SDOS) has a 10-Year RORE % of -17.40 as of Apr. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on ScandiDos AB and its competitors. According to the industry distribution chart, ScandiDos AB ranks #335 out of 428 companies in the Medical Devices & Instruments industry, placing it in the top 78.3%.
Is ScandiDos AB's 10-Year RORE % too high?
ScandiDos AB's current 10-Year RORE % is -17.40. Based on the distribution chart, ScandiDos AB ranks #335 out of 428 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ScandiDos AB has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ScandiDos AB's 10-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ScandiDos AB ranks #335 out of 428 companies for 10-Year RORE %. This places ScandiDos AB in the lower half of its industry. The industry median 10-Year RORE % is 0.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Devices & Instruments company?
The median 10-Year RORE % among Medical Devices & Instruments companies is 0.74, based on 428 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on ScandiDos AB and its competitors. For the Medical Devices & Instruments industry, the median 10-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ScandiDos AB's current 10-Year RORE % is -17.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ScandiDos AB stock overvalued right now?
Based on GuruFocus' analysis, ScandiDos AB (OSTO:SDOS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.14, compared to a current price of kr0.85 — trading 25.4% below its estimated fair value. The current 10-Year RORE % is -17.40. ScandiDos AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For ScandiDos AB (OSTO:SDOS), the current 10-Year RORE % is -17.40 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ScandiDos AB (OSTO:SDOS) Overvalued in 2026?

Based on GuruFocus' analysis, ScandiDos AB stock appears to be undervalued. The current stock price of kr0.85 is trading 25.4% below its estimated GF Value™ of kr1.14. GuruFocus considers ScandiDos AB to be Modestly Undervalued.

Key valuation signals for OSTO:SDOS:

  • 10-Year RORE %: -17.40
  • GF Value™: kr1.14 vs. price of kr0.85 (25.4% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SDOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ScandiDos AB Business Description

Address Uppsala Science Park, Uppsala, SWE, SE-751 83
ScandiDos AB is engaged in providing radiation therapy for cancer. Its product, Delta4 Phantom+, and its various hardware and software options are at the heart of everything ScandiDos does, from product development and production to marketing, sales, and customer support. With Delta4 HexaMotion ScandiDos has successfully developed a motion platform that recreates the movement of the tumor in six dimensions and independently simulates the patient's breathing movement.
47GF Score

Get the complete analysis for OSTO:SDOS

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.85
Price
kr1.14
GF Value